Table 4.
Associations of miR-20a-5p expression levels with clinicopathological features.
| Stroma | Cytoplasm | Nucleus | Cytoplasm and nucleus | ||||||
|---|---|---|---|---|---|---|---|---|---|
| High | Low | High | Low | High | Low | High/high | Low/low | Mixed | |
| Tumor size, cm, median (IQR) | 1.5 (1.3) | 1.7 (1.3) | 1.5 (1.5) | 1.7 (1.2) | 1.5 (1.3) | 1.9 (1.3) | 1.5 (1.5) | 1.9 (1.3) | 1.5 (1.2) |
| p | 0.20 | 0.63 | 0.030* | 0.06 | |||||
| Tumor grade, n (%) | |||||||||
| 1 | 12 (26.1) | 85 (32.4) | 24 (32.9) | 74 (31.1) | 60 (33.5) | 38 (28.8) | 22 (31.0) | 36 (27.7) | 40 (36.4) |
| 2 | 19 (41.3) | 110 (42.0) | 23 (31.5) | 109 (45.8) | 67 (37.4) | 65 (49.2) | 23 (32.4) | 65 (50.0) | 44 (40.0) |
| 3 | 15 (32.6) | 67 (25.6) | 26 (35.6) | 55 (23.1) | 52 (29.1) | 29 (22.0) | 26 (36.6) | 29 (22.3) | 26 (23.6) |
| p | 0.54 | 0.047* | 0.11 | 0.06 | |||||
| Molecular subgroup, n (%) | |||||||||
| Luminal A | 26 (56.5) | 165 (63.0) | 41 (55.4) | 152 (63.9) | 113 (63.1) | 80 (60.6) | 40 (56.3) | 79 (60.8) | 74 (67.3) |
| Luminal B | 10 (21.7) | 53 (20.2) | 15 (20.3) | 49 (20.6) | 36 (20.1) | 27 (20.5) | 13 (18.3) | 26 (20.0) | 24 (21.8) |
| HER2-enriched | 2 (4.4) | 13 (5.0) | 4 (5.4) | 11 (4.6) | 6 (3.4) | 9 (6.8) | 4 (5.6) | 9 (6.9) | 2 (1.8) |
| Basal-like | 8 (17.4) | 31 (11.8) | 14 (18.9) | 26 (10.9) | 24 (13.4) | 16 (12.1) | 14 (19.7) | 16 (12.3) | 10 (9.1) |
| p | 0.73 | 0.30 | 0.56 | 0.21 | |||||
| Ki67, n (%) | |||||||||
| High | 19 (47.5) | 68 (30.9) | 27 (42.9) | 60 (30.2) | 58 (37.2) | 29 (27.4) | 27 (43.6) | 29 (27.6) | 31 (32.6) |
| Low | 21 (52.5) | 152 (69.1) | 36 (57.1) | 139 (69.9) | 98 (62.8) | 77 (72.6) | 35 (56.5) | 76 (72.4) | 64 (67.4) |
| p | 0.041* | 0.06 | 0.10 | 0.11 | |||||
| ER + , n (%) | |||||||||
| Yes | 36 (78.3) | 214 (81.4) | 54 (74.0) | 198 (82.9) | 148 (82.2) | 104 (78.8) | 53 (74.7) | 103 (79.2) | 96 (85.5) |
| No | 10 (21.7) | 49 (18.7) | 19 (26.0) | 41 (17.2) | 32 (17.8) | 28 (21.2) | 18 (25.4) | 27 (20.8) | 15 (13.5) |
| p | 0.62 | 0.09 | 0.45 | 0.12 | |||||
| PR + , n (%) | |||||||||
| Yes | 29 (65.9) | 173 (67.8) | 49 (68.1) | 153 (66.5) | 118 (68.2) | 84 (65.1) | 47 (67.1) | 82 (64.6) | 73 (69.5) |
| No | 15 (34.1) | 82 (32.2) | 23 (31.9) | 77 (33.5) | 55 (31.8) | 45 (34.9) | 23 (32.9) | 45 (35.4) | 32 (30.5) |
| p | 0.80 | 0.81 | 0.57 | 0.73 | |||||
| HER2 + , n (%) | |||||||||
| Yes | 6 (13.0) | 32 (12.2) | 7 (9.6) | 31 (13.0) | 20 (11.2) | 18 (13.6) | 6 (8.5) | 17 (13.1) | 15 (13.6) |
| No | 40 (87.0) | 230 (87.8) | 66 (90.4) | 207 (87.0) | 159 (88.8) | 114 (86.4) | 65 (91.6) | 113 (86.9) | 95 (86.4) |
| p | 0.88 | 0.43 | 0.51 | 0.54 | |||||
| Relapse, n (%) | |||||||||
| Yes | 8 (17.4) | 17 (6.5) | 7 (9.7) | 18 (7.6) | 18 (10.1) | 7 (5.3) | 7 (10.0) | 7 (5.4) | 11 (9.9) |
| No | 38 (82.6) | 244 (93.5) | 65 (90.3) | 220 (92.4) | 161 (89.9) | 124 (94.7) | 63 (90.0) | 122 (95.6) | 100 (90.1) |
| p | 0.013* | 0.55 | 0.13 | 0.35 | |||||
| Lymph node metastasis, n (%) | |||||||||
| Yes | 16 (34.8) | 76 (29.1) | 16 (21.9) | 78 (32.9) | 46 (25.7) | 48 (36.6) | 16 (22.5) | 48 (37.2) | 30 (27.3) |
| No | 30 (65.2) | 185 (70.9) | 57 (78.1) | 159 (67.1) | 133 (74.3) | 83 (63.4) | 55 (77.5) | 81 (62.8) | 80 (72.7) |
| p | 0.44 | 0.07 | 0.038* | 0.07 | |||||
| Distant metastasis, n (%) | |||||||||
| Yes | 5 (11.1) | 28 (10.7) | 8 (11.1) | 26 (11.0) | 16 (9.0) | 18 (13.7) | 8 (11.4) | 18 (14.0) | 8 (7.3) |
| No | 40 (88.9) | 233 (89.3) | 64 (88.9) | 211 (89.0) | 162 (91.0) | 113 (86.3) | 62 (88.6) | 111 (86.1) | 102 (92.7) |
| p | 0.94 | 0.97 | 0.19 | 0.26 | |||||
Associations between clinicopathological features and miR-20a-5p expression in tumor stromal fibroblasts (stroma), cancer cell cytoplasm (cytoplasm), cancer cell nuclei (nucleus), and cancer cell compartments combined. ER estrogen receptor, HER2 human epidermal growth factor receptor 2, IQR interquartile range, PR progesterone receptor, SD standard deviation. *Statistically significant (p < 0.05).